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We investigated the eﬀects of clopidogrel on reperfusion and inﬂammatory process in STEMI. A total of 175 STEMI patients
with similar clinical characteristics were included to this study. One was the standard pharmacological reperfusion therapy group
(group 1, n : 90), who received 300mg aspirin, 70U/kg bolus, and 12U/kg/hr continuous infusion of unfractioned heparin and
accelerated t-PA.Clopidogrel450mgloading and75mg/dthereafter was addedtostandardreperfusiontherapyinthe othergroup
(group 2, n : 85). The ST-segment resolution, CK-MB, and high-sensitive CRP (hs-CRP) parameters were measured. Complete ST
resolution was observed in 32 patients (36.8%) in group 1 and 53 patients (63.8%) in group 2 (P<. 001). Also in the ﬁrst 24 hours,
theCK-MBlevels ofpatients in group 1were signiﬁcantly higher than thoseof group 2(P = .001). Thehs-CRPvalues were greater
i ng r o u p1t h a ng r o u p2a t4 8 t hh o u r( g r u o p1 :9 .4 ± 0.1mg/L,group2:3.7 ± 1.4mg/L;P = .000). We concluded that adding
clopidogrel to standard treatment in STEMI patients provided early reperfusion and suppression of inﬂammatory response.
Copyright © 2009 Mehmet Akbulut et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Thromboxane and ADP, which are among the mediators
of platelet activation and aggregation, play a key role in
initiating and propagating coronary thrombosis and are
raisedduringmyocardialinfarction.Simultaneousinhibition
of both of these pathways with the combination of clopi-
dogrel and aspirin produces greater antiplatelet eﬀects than
either agent alone [1, 2]. In recent reports, dual antiplatelet
therapy with aspirin and clopidogrel showed signiﬁcant
improvements on prognosis in ST-elevating myocardial
infarction (STEMI) [3–5]. Moreover, this beneﬁcial eﬀect is
not only limited to the acute phase, but also extended to
a 1-year follow-up period [6]. But substantial uncertainty
remained regarding the net eﬀects of adding clopidogrel to
aspirin upon the reperfusion, acute inﬂammatory response,
and ischemic events in this setting. In this study, we
evaluated the eﬀect of the addition of clopidogrel to standard
reperfusion protocol on reperfusion and acute inﬂammatory
response.
2.MaterialandMethods
2.1. Patient Population. From December 2006 to January
2008, consecutive patients were enrolled who presented
with ischemic discomfort lasting >20 minutes at rest
within 12 hours, before randomization pain lasting >20
minutes, ST-segment elevation of at least 0.2mV in at
least two contiguous precordial leads. The study was
limited to only anteriorly located myocardial infarction
to homogenize the investigated population. The exclusion
criteria were conduction or rhythm abnormalities (bundle
branch block, idioventricular rhythm, etc.); any contraindi-
cation to thrombolytics [7]; early coronary angiography
(within ﬁrst 48 hours) due to recurrent ischemia or
failed thrombolysis; those patients under the treatment of
aspirin or thienopyridines; any contraindication to aspirin
or clopidogrel; past history of MI or coronary revas-
cularization; presence of clinically assessed heart failure
(Killip II/III) or cardiogenic shock; hepatic failure; renal
failure (serum creatinine >2.5mg/dL); thrombocytopenia2 Mediators of Inﬂammation
Table 1: Baseline characteristics.
Characteristics Group 1 (n : 87) Group 2 (n : 83) P value
Mean age (year) 57 ± 75 6 ± 5. 3 1
Men (%) 79.3 80.7 .48
Time for symptom to lytic (h) 2.7 ± 22 . 6 ± 1. 5 6
Presentation
Heart rate (beat/min) 75 ± 14 74 ± 12 .37
Systolic blood pressure (mmHg) 133 ± 14 135 ± 16 .31
Diastolic blood pressure (mmHg) 73 ± 11 75±15 .29
History (%)
Current smoker 44.8 44.6 .51
Diabetes mellitus 17.2 19.3 .44
Hypertension 29.9 32.5 .35
Hyperlipidemia 27.6 31.3 .35
High TIMI risk score (≥5) 13.8 14.8 .33
Medication during hospitalization (%)
β-blocker 93 94 .50
Statins 90 93 .51
ACE-I or ARB 73 74 .43
(<100.000/mm3) and patients older than 70 years old were
excluded.
The study protocol was approved by institutional review
board, and written informed consent was taken from all
patients.
2.2. Study Design. A total of 175 patients were included in
thepresentstudyandwereallocatedin2groups.Onewasthe
standard pharmacological reperfusion therapy group (group
1, n : 90), consisting of patients who received 300mg aspirin
atﬁrstthen150mg/dthereafter,70U/kg(maximum5000U)
bolus, and 12U/kg/hr continuous infusion of unfractioned
heparin and accelerated t-PA therapy (15mg intravenous
bolus followed by an infusion of 0.75mg/kg (maximum
50mg)over30minutes,followedbyaninfusionof0.5mg/kg
(maximum 35mg) over 60 minutes). Clopidogrel 450mg
loading and 75mg/d thereafter was added to standard
reperfusion therapy in the other group (group 2, n : 85).
The ST-segment resolution within 120 minutes, CK-MB
parameters within ﬁrst 24 hours, and high-sensitive C-
reactive protein (hs-CRP) parameters within 48 hours were
measured. Also patients were examined for inhospital major
and minor bleeding complications. All data were evaluated
b yt w oi n v e s t i g a t o r sw h oa r eb l i n d e dt ot r e a t m e n t .
2.2.1. Electrocardiographic Analysis. Standard 12-lead elec-
trocardiograms were obtained at baseline and at 30-minute
periods during the ﬁrst120 minutes after initiation of ﬁbri-
nolytictherapy.ST-segmentelevationwasanalyzedmanually
with lens-intensiﬁed calipers to the nearest of 0.025mV 20
milliseconds after the end of QRS complex with the PR
segment as the reference baseline from leads I, aVL, and V1
through V6 for anterior infarction. The sum of ST deviation
wasmeasuredatbaselineandat30,60,90,120minutesusing
previously described methods [8]. The percent resolution of
ST deviation from baseline to 30, 60, 90, 120 minutes was
calculatedandcategorizedascomplete(≥70%),partial(30%
to 70%), or no resolution (≤30%).
2.2.2. Blood Sampling. Blood samples were obtained for
CK-MB and hs-CRP analysis at 0, 4, 8, 12, 24 and 0,
24, 48 hours of admission, respectively. Biochemical and
haematological parameters were measured by an Olympus
AU600autoanalyzer(OlympusOpticalCo.,Ltd.,Schimatsu-
Mishima, Japan) and Bayer Advia 120 Cell CBC Counter
Hematologia autoanalyzer (Bayer Advia 120 CBC counter,
NJ, USA). Hs-C-reactive protein was measured by the high-
sensitivity nephelometric method (Dade Behring, Marburg,
Germany).
2.3. Statistical Analysis. T h eS P S Sf o rw i n d o w sp r o g r a m
(version 15.0) was used for all data analysis. Study data
were expressed as mean value ± standard deviation or per-
cent values. Numerical variables were compared by Mann-
Whiney U-test, whereas nonnumerical ones were compared
by Chi-squere test. Results with a P value less than .05 were
considered statistically signiﬁcant.
3. Results
3.1. Baseline Characteristics. A total of 175 patients were
included in the study (group 1, n : 90; group 2, n : 85).
Three patients due to ischemic events in group 1 (2 failed
thrombolysis, 1 heart failure) and patients in group 2 were
excluded from the study due to ischemic and hemorrhagic
events (1 heart failure, 1 gluteal hemorrhage). However,
there were no important diﬀerences in baseline clinical
characteristics and initial therapy between the two treatment
groups. Clinical characteristics of the study groups were
shown in Table 1.Mediators of Inﬂammation 3
Table 2: Number of patients with resolution in 120th minute.
Group 1 (n : 87) Group 2 (n : 83) P value
>70% 36.8 (32) 63.8 (53) .001
30–70% 49.4 (43) 27.7 (23) .001
<30% 13.8 (12) 8.4 (7) .01
P<. 001
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Figure 1: 120 minute ST-segment resolution.
3.2. ST-Segment. Complete ST resolution was achieved in 32
of patients (36.8%) in group 1 and 53 of patients (63.8%)
in group 2 (P < .001) at the end of 120 minutes (Table 2
and Figure 1). The diﬀerence between groups started after
60th minute of the therapy, and it became more signiﬁcant
at 120th minute (Figure 2).
3.3. CK-MB. Peak CK-MB values were reached at
10–12th hours in group 1, whereas in group 2 they were at
8–10th hours. Peak CK-MB value was 233.5 ± 145U/L in
group 1 and 132.5 ± 122U/L in group 2 (P = .01), and at the
end of 24 hours CK-MB value was 138 ± 88U/L in group 1,
and 56 ± 35U/L in group 2 (P = .001) (Table 3).
3.4. The hs-CRP. Although baseline hs-CRP values were
similar at baseline (group 1: 1.6 ± 0.9mg/L, group 2: 1.9 ±
1.3mg/L; P = .67), they were greater in group 1 than group 2
at48thhour(group1:9.4±0.1mg/L,group2:3.7±1.4mg/L;
P = .000) (Figure 3).
3.5. Other Clinical Outcome. No death was observed in both
groups. Failed thrombolysis in two patients and heart failure
in one patient were seen in group 1; one patient with heart
failure and one patient with major hemorrhage (≥2 unit
blood transfusion) were seen in group 2. However, there is
no signiﬁcant diﬀerence between the groups with respect to
these unfavorable events (P > .05).
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Figure 2: Patient number with ST-segment resolution in the course
of time.
4. Discussion
Platelet activation and aggregation play a key role ini-
tiating and propagating coronary artery thrombosis, and
antiplatelet therapy improves outcomes across the spectrum
of acute coronary syndromes. Beside this, it was thought
that simultaneous inhibition of platelet activation and
aggregation pathways with speciﬁc antiplatelet combinations
might be more eﬃcient in acute coronary syndromes [1,
2]. We observed improvements in both reperfusion and
inﬂammatory response with the early addition of clopi-
dogrel to standard reperfusion therapy in STEMI patients
in this study. Moreover, these ﬁndings supported the
hypothesis of dual antiplatelet inhibition with aspirin and
clopidogrel might be more beneﬁcial in acute coronary
syndrome.
Currently, there are promising developments in the
prevention of ischemic complications in sympthomatic
atherothrombotic cases. The CLARITY-TIMI 28 study
demonstrated that the addition of clopidogrel to aspirin in
patients with STEMI receiving ﬁbrinolytic therapy improved
the patency rate of the infarct-related artery after 48
hours and reduced ischemic complications [3]. Among the
patients in this trial who underwent percutaneous coronary
intervention (PCI), described in the PCI-CLARTY substudy,
clopidogrel pretreatment signiﬁcantly reduced the incidence
of cardiac death or ischemic complications both before
and after PCI [9]. In the COMMIT trial, the routine
addition of clopidogrel 75mg/d to aspirin therapy for 4
weeks in patients with acute myocardial infarction resulted
in a 9% proportional reduction in death, reinfarction, or
stroke (P = .002) and a 7% proportional reduction in
death (P = .03) [5]. Even though no loading dose was
used, the beneﬁt of clopidogrel therapy was seen almost
immediately by an 11% proportional reduction in mortality
in the ﬁrst 2 days after the initiation of therapy (P =
.019) [5]. The results of both CLARITY-TIMI 28 and
COMMIT showed that adding clopidogrel to aspirin and
other standard treatments safely reduced mortality and
major vascular events in patients with acute myocardial
infarction.
Beneﬁcial eﬀects of clopidogrel may arise through
some diﬀerent proposed mechanisms. (i) Clopidogrel may4 Mediators of Inﬂammation
Table 3: CK-MB (U/L) levels of the patients in the groups during the ﬁrst 24 hours.
0 hour 4th hour 8th hour 12th hour 24th hour
Group I 29.2 ± 23 106.4 ± 54 193.2 ± 125 233.5 ± 145 138 ± 88
Group II 28.5 ± 22 55.4 ± 35 132.5 ± 122 111.3 ± 27 56 ± 35
P value .66 .006 .01 .001 .001
P = .67
P = 0
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Figure 3:hs-CRPlevelsofthepatientsinthegroupsduringtheﬁrst
48 hours.
facilitate initial ﬁbrinolysis and thereby improve early reper-
fusion with a glycoprotein IIb-IIIa inhibitor [10]-like eﬀect.
(ii) Clopidogrel may exert its eﬀects in myocardial infarction
mainly by preventing reocclusion or by limiting microvas-
cular eﬀects of platelet activation rather than enhancing
ﬁbrinolysis [5]. While most of the beneﬁt of clopidogrel has
been attributed to inhibition of platelet activation, blockage
of the P2Y12 receptor may also have pleotropic eﬀects with
respect to endothelial cell function, leukocyte activation, and
inﬂammation [11].
Previous studies have suggested some anti-inﬂammatory
properties of clopidogrel. A reduction in the number of
platelet-leukocyte interactions has been described [12, 13],
and one study reported a special beneﬁt of the drug in
reducing the augmented risk of percutaneous interventions
in patients with elevated levels of C-reactive protein [14].
In another study, it was stated that clopidogrel pretreat-
ment attenuated the periprocedural increase in CRP by
65% [15]. Quinn et al. said that clopidogrel pretreatment
reduces platelet inﬂammatory marker expression in patients
undergoing PCI [16], and they also concluded that it might
be very important for clinical events. All these ﬁndings
constituted an important clue for us to investigate the
limiting eﬀect of clopidogrel in increment of high-sensitive
C-reactive protein in STEMI and to verify this. Moreover,
we could not see another study in literature about this
topic.
Activated platelets have been clearly implicated in the
tendency for microembolization during acute coronary
syndrome [17, 18] and play an important role in the
inﬂammatory response. Studies have shown that activated
platelets express the CD40 ligand, a potent stimulus of
vascular inﬂammation [19, 20]. The CD40 ligand promotes
platelet-leukocyte interactions [19] and induces tissue factor
expression [21], thus providing a link among inﬂamma-
tion, platelet activation, embolization, and coagulation. The
inhibition of subcellular platelet CD40 ligand by clopidogrel
treatment may explain the mechanism of reduction in
inﬂammation as expressed by an attenuation in C-reactive
protein increase after acute STEMI. By the way, we think
that large extensive clinical trials are needed to exactly
clarify the mechanisms of beneﬁcial eﬀects of clopidogrel
on clinical results in previous ones and that is what
we have determined in our study because the impressive
improvement in clinical results with added clopidogrel on
aspirin requires some other mechanisms except for a potent
antiplatelet eﬀect.
5. Limitations
The ﬁrst and most important limitation is the small study
population and the lack of a placebo control group. Only
the anteriorly located STEMI patients were included to
homogenize the study population, and a ﬁbrinolytic agent
only rt-PA was used and this condition was an important
limiting factor for our study. Clopidogrel loading dose
(450mg) may be a limitation. We think that diﬀerent
dosages (300–600mg) should be applied for both evalu-
ations of safety and eﬃcacy because there is a correla-
tion between loading dose and time to reach maximal
antiplatelet eﬀect [22]. Another limiting factor of our
study was the restriction of the study with 48 hours. A
long follow-up period would be more useful to exactly
realize all the eﬃciency and safety of clopidogrel (major
and minor hemorrhages included) treatment. So that with
long follow-up period, diﬀerence among the groups of
medical treatment, PCI and coronary artery bypass grefting
in the direction of angiographic ﬁndings could be clearly
understood.
6. Conclusions
In conclusion, we found that addition of clopidogrel to
medical reperfusion therapy in STEMI had favorable eﬀects
on reperfusion and suppression of hs-CRP. We think
that these favorable clinical and laboratory eﬀects of dual
antiplatelet therapy with clopidogrel are not only limited to
its antiplatelet eﬀect, but also there may be some pleiotropic
eﬀects of clopidogrel; those were not explained clearly. Large
extensive studies are needed to explain the complete eﬀect of
clopidogrel in acute STEMI.Mediators of Inﬂammation 5
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